Seres Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Seres Therapeutics is a biotechnology research company based in Cambridge, Massachusetts, focused on developing microbiome-based therapies for serious diseases. Its lead product, VOWST, received U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapy to prevent recurrence of Clostridioides difficile infection after antibiotic treatment, and it is being commercialized in collaboration with Nestlé Health Science. The organization operates as a mid-sized biotechnology firm.

Beyond VOWST, Seres is advancing SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce gastrointestinal infections, bloodstream infections, and graft-versus-host disease. The company is pursuing additional preclinical programs targeting infection protection in medically compromised patients and researching microbiome therapeutics for ulcerative colitis, and it recently presented preclinical data on SER-603 for inflammatory bowel disease at Digestive Disease Week 2026.

Sign up for free to view info

Email Format Employee directory